Drug Information

Drug General Information
Drug ID
D07UKJ
Former ID
DNCL002162
Drug Name
Enavatuzumab
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [532085]
Company
Abbott Laboratories
Target and Pathway
Target(s) TNF superfamily receptor 12A Target Info [532085]
KEGG Pathway Cytokine-cytokine receptor interaction
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Reactome TNFR2 non-canonical NF-kB pathway
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways TWEAK Signaling Pathway
References
Ref 532085Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
Ref 532085Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.